PROLIPOSOMAL AND LIPOSOMAL COMPOSITIONS OF POORLY WATER SOLUBLE DRUGS

• US 20090017105A1
• Filed: 03/11/2008
• Published: 01/15/2009
• Est. Priority Date: 03/19/2007
• Status: Abandoned Application

• Current Assignee: Fresenius KABI Oncology Limited (Else Kröner-Fresenius-Stiftung)
• Original Assignee: Fresenius KABI Oncology Limited (Else Kröner-Fresenius-Stiftung)
• Inventors: Awasthi, Anshumali, Jaggi, Manu, Kumar, Mukesh, Singh, Anu T., Burman, Anand C., Khattar, Dhiraj, Garg, Minakshi, Mukherjee, Rama
• Application Number:
  US12/045,958
• Publication Number:
  US 20090017105A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: A61K 9/1277 Processes for preparing; Proliposomes
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ≧95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.

Claims

1. A proliposomal composition comprising a concentrate of:

a) a membrane forming lipid comprising of one or more of a saturated phospholipid, an unsaturated phospholipid, or mixtures thereof;

b) a membrane stabilizing agent selected from a sterol compound;

c) a vehicle for the lipids selected from a water-miscible organic solvent or mixtures thereof; and

d) one or more poorly water-soluble drugs and compounds,

contained in sterile glass vials, sterile vials made of non-toxic materials, or pre-filled sterile syringes, wherein the proliposomal composition forms liposomes of the one or more water-soluble drugs and compounds upon injection into a diluting fluid.

2. The composition according to claim 1, further comprising one or more of a Polyethylene Glycol (PEG)-coupled phospholipid and pharmaceutically acceptable excipients.

4. The composition according to claim 1, wherein the one or more poorly water-soluble drugs and compounds belong to the class of anticancer agents selected from Paclitaxel, Docetaxel, Irinotecan, Topotecan, SN-38, Doxorubicin, Daunomycin, Cisplatin, Oxaliplatin, 5-Fluorouracil, Mitomycin, Methotrexate, Etoposide, Wedelolactone, Betulinic acid, a Betulinic acid derivative of formula (I);

a Betulinic acid of formula (II);

or a Betulinic acid of formula (III);

anti-inflammatory agents selected from Indomethacin, Ibuprofen, Ketoprofen, Flubiprofen, Piroxicam, Tenoxicam, or Naproxen;

anti-fungal agents selected from Ketoconazole or Amphotericin B;

sex hormones selected from Testosterone, Estrogen, Progesterone, or Estradiol;

steroids selected from Dexamethasone, Prednisolone, Fulvestrant, Exemestane, or Triamcinolone;

antihypertensive agents selected from Captopril, Ramipril, Terazosin, Minoxidil, or Parazosin;

antiemetics selected from Ondansetron or Granisetron;

antibiotics selected from Metronidazole or Fusidic acid;

immunomodulators selected from Cyclosporine or Biphenyl dimethyl dicarboxylic acid; and

anaesthetics selected from Propofol, Alfaxalone, or Hexobarbital.

9. A composition according to claim 1, wherein the membrane forming lipid is a saturated phospholipid selected from Hydrogenated soya phosphatidylcholine (HSPC), Hydrogenated Soya lecithin, Dimyristoyl phosphatidyl ethanolamine (DMPE), Dipalmitoyl phosphatidyl ethanolamine (DPPE), Dimyristoyl Phosphatidylcholine (DMPC), Dipalmitoyl Phosphatidylcholine (DPPC), Distearoylphosphatidyl choline (DSPC), Dilauroyl phosphatidylcholine (DLPC), 1-myristoyl-2-palmitoyl phosphatidylcholine, 1-palmitoyl-2-myristoyl phosphatidylcholine, 1-Palmitoyl phosphatidylcholine, 1-stearoyl-2-palmitoyl Phosphatidylcholine, Dipalmitoyl Sphingomyelin, Distearoyl Sphingomyelin, Hydrogenated phosphatidyl inositol (HPI), Dimyristoyl phosphatidyl glycerol (DMPG), Dipalmitoyl phosphatidyl glycerol (DPPG), Distearoyl phosphatidyl glycerol (DSPG), Dimyristoyl phosphatidic acid (DMPA), Dipalmitoyl phosphatidic acid (DPPA), Dimyristoyl phosphatidyl serine (DMPS), Dipalmitoyl phosphatidyl serine (DPPS), Diphosphatidyl glycerol (DPG), Hydrogenated Soya phosphatidyl glycerol (SPG-3), Dioleoyl phosphatidyl glycerol (DOPG), Distearoyl phosphatidic acid (DSPA), or mixtures thereof.

12. A composition according to claim 1, wherein the membrane forming lipid is an unsaturated phospholipid selected from Lecithin, Phosphatidylcholine (PC), Phosphatidyl ethanolamine (PE), Lysolecithin, Lysophosphatidyl ethanolamine, Dilaurylphosphatidyl choline (DLPC), Dioleoyl phosphatidyl choline (DOPC), Sphingomyelin, Brain Sphingomyelin, Cerebrosides, Egg Phosphatidyl glycerol (EPG), Soya phosphatidyl glycerol (SPG), Phosphatidyl inositol (PI), Phosphatidic acid (PA), Phosphatidyl serine (PS), Dilauroyl phosphatidyl glycerol (DLPG), Cardiolipins, or mixtures thereof.

15. A composition according to claim 1, wherein the membrane stabilizing agent is a sterol compound selected from Cholesterol, Cholesterol derivatives, Vitamin D, Cholesteryl esters, or mixtures thereof.

18. A composition according to claim 1, wherein the vehicle is a water-miscible organic solvent selected from ethanol, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, diethyl sulfoxide, polyethylene glycols, and propylene glycol, or mixtures thereof.

21. A composition according to claim 2, wherein the Polyethylene Glycol (PEG)-coupled lipids are selected from Carbonyl methoxypolyethylene glycol-distearoyl phosphatidyl ethanolamine, Carbonyl methoxypolyethylene glycol-dipalmitoyl phosphatidyl ethanolamine, or Carbonyl methoxypolyethylene glycol-dimyristoyl phosphatidyl ethanolamine.

24. A composition according to claim 2, wherein the pharmaceutically acceptable excipient is an antioxidant selected from α

-Tocopherol or its acetate salt, Vitamin E, β

-carotene, α

-Carotene, Lycopene, Lutein, or Zeaxanthine.

27. A composition according to claim 2, wherein pharmaceutically acceptable excipient is a buffering is selected from citrate buffer, tris-buffer, or phosphate buffer.

44. A process for preparation of the liposomal composition comprising

a) a membrane forming lipid comprising of one or more of a saturated phospholipid, an unsaturated phospholipid, or mixtures thereof;

b) a membrane stabilizing agent selected from a sterol compound;

c) a vehicle for the lipids selected from a water-miscible organic solvent or mixtures thereof;

d) a diluting fluid; and

e) one or more poorly water-soluble drugs and compounds

wherein the liposomal composition is characterized by a physical stability of not less than 4 hours, ≧

95% encapsulation of the one or more poorly water-soluble drugs and compounds in the liposomes, having a particle size diameter of less than 100 nm, comprising injection of the concentrate of the proliposomal composition of claim 1, through syringes, fitted with hypodermic needles of gauge 18 G to 30 G into a diluting fluid at a rate of about 0.10 ml/second to about 1.5 ml/second.

3. (canceled)

5-8. -8. (canceled)

10-11. -11. (canceled)

13-14. -14. (canceled)

16-17. -17. (canceled)

19-20. -20. (canceled)

22-23. -23. (canceled)

25-26. -26. (canceled)

28-29. -29. (canceled)

30. A liposomal comprising of:

a) a membrane forming lipid comprising of one or more of a saturated phospholipid, an unsaturated phospholipid, or mixtures thereof;

b) a membrane stabilizing agent selected from a sterol compound;

c) a vehicle for the lipids selected from a water-miscible organic solvent or mixtures thereof;

d) a diluting fluid, and

e) one or more poorly water-soluble drugs and compounds.

31. The composition according to claim 30, further comprising of a Polyethylene Glycol (PEG)-coupled phospholipid and pharmaceutically acceptable excipients.

32. A composition according to claim 30, wherein:

a. the one or more poorly water-soluble drugs and compounds have water solubility of less than 10 mg/ml;

b. the membrane forming lipids are saturated phospholipids selected from Hydrogenated soya phosphatidylcholine (HSPC), Hydrogenated Soya lecithin, Dimyristoyl phosphatidyl ethanolamine (DMPE), Dipalmitoyl phosphatidyl ethanolamine (DPPE), Dimyristoyl Phosphatidylcholine (DMPC), Dipalmitoyl Phosphatidylcholine (DPPC), Distearoylphosphatidyl choline (DSPC), Dilauroyl phosphatidylcholine (DLPC), 1-myristoyl-2-palmitoyl phosphatidylcholine, 1-palmitoyl-2-myristoyl phosphatidylcholine, 1-Palmitoyl phosphatidylcholine, 1-stearoyl-2-palmitoyl Phosphatidylcholine, Dipalmitoyl Sphingomyelin, Distearoyl Sphingomyelin, Hydrogenated phosphatidyl inositol (HPI), Dimyristoyl phosphatidyl glycerol (DMPG), Dipalmitoyl phosphatidyl glycerol (DPPG), Distearoyl phosphatidyl glycerol (DSPG), Dimyristoyl phosphatidic acid (DMPA), Dipalmitoyl phosphatidic acid (DPPA), Dimyristoyl phosphatidyl serine (DMPS), Dipalmitoyl phosphatidyl serine (DPPS), Diphosphatidyl glycerol (DPG), Hydrogenated Soya phosphatidyl glycerol (SPG-3), Dioleoyl phosphatidyl glycerol (DOPG), Distearoyl phosphatidic acid (DSPA), or mixtures thereof;

c. the membrane stabilizing agents are sterol compounds selected from Cholesterol, Cholesterol derivatives, Vitamin D, Cholesteryl esters, or mixtures thereof; and

d. the vehicles are water-miscible organic solvents selected from ethanol, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, diethyl sulfoxide, polyethylene glycols propylene glycol, or mixtures thereof.

38. A composition according to claim 31, wherein:

a) the Polyethylene Glycol (PEG)-coupled lipids are selected from Carbonyl methoxypolyethylene glycol-distearoyl phosphatidyl ethanolamine, Carbonyl methoxypolyethylene glycol-dipalmitoyl phosphatidyl ethanolamine, or Carbonyl methoxypolyethylene glycol-dimyristoyl phosphatidyl ethanolamine; and

b) the pharmaceutically acceptable excipients are antioxidants selected from α

-Tocopherol or its acetate salt, Vitamin E, β

-carotene, α

-Carotene, Lycopene, Lutein, or Zeaxanthine.

33-37. -37. (canceled)

39. (canceled)

40. A process for preparation of the proliposomal composition comprising

a membrane forming lipid comprising of one or more of a saturated phospholipid, an unsaturated phospholipid, or mixtures thereof;

a membrane stabilizing agent selected from a sterol compound; and

a vehicle for the lipids selected from a water-miscible organic solvent or mixtures thereof; and

one or more poorly water-soluble drugs and compounds,

wherein the process comprises the steps of;

a) mixing together the membrane forming lipids and the membrane stabilizing agent in the vehicle at a temperature of between 30°

C. to 70°

C. to obtain a clear solution;

b) cooling the clear solution of step a) to room temperature;

c) adding one or more poorly water-soluble drugs and compounds either as a solid or as a mixture in the vehicle to the solution of step b);

d) mixing the contents of step c) to obtain a clear solution;

e) diluting the mixture of step d) with the vehicle;

f) filtering the solution of step e) through sterile filters to obtain a concentrate of the proliposomal composition; and

g) filling the concentrate of step f) into glass vials, vials made of non-toxic materials, or syringes.

41. (canceled)

42. A process for preparation of the proliposomal composition comprising

a membrane forming lipid comprising of one or more of a saturated phospholipid, an unsaturated phospholipid, or mixtures thereof;

a membrane stabilizing agent selected from a sterol compound; and

a vehicle for the lipids selected from a water-miscible organic solvent or mixtures thereof;

one or more poorly water-soluble drugs and compounds, and

one or more of a Polyethylene Glycol (PEG)-coupled phospholipid and pharmaceutically acceptable excipients, wherein the process comprises the steps of;

a) mixing together the membrane forming lipids, the membrane stabilizing agent, the (PEG)-coupled phospholipids, and the pharmaceutically acceptable antioxidant and/or the pharmaceutically acceptable acidifying agent in the vehicle, at a temperature of between 30°

C. to 70°

C. to obtain a clear solution;

b) cooling the clear solution of step a) to room temperature;

c) adding one or more poorly water-soluble drugs and compounds either as a solid or as a mixture in the vehicle to the solution of step b);

d) mixing the contents of step c) to obtain a clear solution;

e) optionally adjusting the pH of the solution of step d) with a pharmaceutically acceptable buffering agent;

f) diluting the mixture of step d) or e) further with the vehicle;

g) filtering the solution of step f) through sterile filters to obtain a concentrate of the proliposomal composition; and

h) filling the concentrate of step g) into glass vials, vials made of non-toxic materials, or syringes.

43. (canceled)

45-46. -46. (canceled)

47. A method of treatment of pathological conditions in humans and other animals comprising administration of a liposomal composition comprising

a membrane forming lipid comprising of one or more of a saturated phospholipid, an unsaturated phospholipid, or mixtures thereof;

b) a membrane stabilizing agent selected from a sterol compound;

c) a vehicle for the lipids selected from a water-miscible organic solvent or mixtures thereof;

d) a diluting fluid, and

e) one or more poorly water-soluble drugs and compounds.

48. The method according to claim 47, wherein the one or more poorly water-soluble drugs and compounds belong to the class of anticancer agents selected from Paclitaxel, Docetaxel, Irinotecan, Topotecan, SN-38, Doxorubicin, Daunomycin, Cisplatin, Oxaliplatin, 5-Fluorouracil, Mitomycin, Methotrexate, Etoposide, Wedelolactone, Betulinic acid, a Betulinic acid of formula (I);

a Betulinic acid of formula (II);

or a Betulinic acid of formula (III);

anti-inflammatory agents selected from Indomethacin, Ibuprofen, Ketoprofen, Flubiprofen, Piroxicam, Tenoxicam, or Naproxen;

anti-fungal agents selected from Ketoconazole, or Amphotericin B;

sex hormones selected from Testosterone, Estrogen, Progesterone, or Estradiol;

steroids selected from Dexamethasone, Prednisolone, Fulvestrant, Exemestane, or Triamcinolone;

antihypertensive agents selected from Captopril, Ramipril, Terazosin, Minoxidil, or Parazosin;

antiemetics selected from Ondansetron or Granisetron;

antibiotics selected from Metronidazole or Fusidic acid;

immunomodulators selected from Cyclosporine or Biphenyl dimethyl dicarboxylic acid; and

anaesthetics selected from Propofol, Alfaxalone, or Hexobarbital.

52. A method according to claim 47, wherein the method comprises intravenous, intramuscular, or subcutaneous injections.

49-51. -51. (canceled)